Although more than 50% of anakinra-treated patients achieve remission and can stop rIL-1RA therapy within one year [32], other sJIA patients fail to completely respond to IL-1 blocking therapy necessitating the concomitant use of glucocorticoids and/or switch to IL-6 blocking therapy [33, 34]. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.